Pneumonia is the leading cause of death due to infectious disease. This issue of Infectious Disease Clinics, guest edited by Tom File, focuses on the controversies and questions surrounding community-acquired pneumonia, including the potential benefits of identifying biomarkers for management of CAP (which could someday become a part of routine diagnostic testing for CAP), the best therapies for influenza/viral causes of pneumonia (the most common form of the disease in children), and clinical scoring tools to help predict long term outcomes. The issue also discusses how to approach MRSA as a cause of CAP and how to approach the non-responding patient.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Preface - p. 6 7. Erratum - p. 7 8. Is the Present Definition of Health Care–Associated Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens? - p. 8 9. Biomarkers - p. 17 10. Clinical Scoring Tools - p. 24 11. What Is the Role of Newer Molecular Tests in the Management of CAP? - p. 31 12. Guidelines and Quality Measures - p. 43 13. What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?) - p. 51 14. Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP? - p. 57 15. Does Empirical Therapy with a Fluoroquinolone or the Combination of a β-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward? - p. 66 16. What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents) - p. 75 17. How Important Are Anaerobic Bacteria in Aspiration Pneumonia - p. 84 18. What is the Role of Respiratory Viruses in Community-Acquired Pneumonia? - p. 88 19. How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy? - p. 96 20. What Is the Best Approach to the Nonresponding Patient with Community-Acquired Pneumonia? - p. 103 21. What is the Association of Cardiovascular Events with Clinical Failure in Patients with Community-Acquired Pneumonia? - p. 110 22. What is the Role of Antimicrobial Stewardship in Improving Outcomes of Patients with CAP? - p. 113 23. How Effective is Vaccination in Preventing Pneumococcal Disease? - p. 120 24. Index - p. 127
No hay muestra disponible
No hay ficha técnica disponible
Pneumonia is the leading cause of death due to infectious disease. This issue of Infectious Disease Clinics, guest edited by Tom File, focuses on the controversies and questions surrounding community-acquired pneumonia, including the potential benefits of identifying biomarkers for management of CAP (which could someday become a part of routine diagnostic testing for CAP), the best therapies for influenza/viral causes of pneumonia (the most common form of the disease in children), and clinical scoring tools to help predict long term outcomes. The issue also discusses how to approach MRSA as a cause of CAP and how to approach the non-responding patient.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Preface - p. 6 7. Erratum - p. 7 8. Is the Present Definition of Health Care–Associated Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens? - p. 8 9. Biomarkers - p. 17 10. Clinical Scoring Tools - p. 24 11. What Is the Role of Newer Molecular Tests in the Management of CAP? - p. 31 12. Guidelines and Quality Measures - p. 43 13. What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?) - p. 51 14. Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP? - p. 57 15. Does Empirical Therapy with a Fluoroquinolone or the Combination of a β-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward? - p. 66 16. What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents) - p. 75 17. How Important Are Anaerobic Bacteria in Aspiration Pneumonia - p. 84 18. What is the Role of Respiratory Viruses in Community-Acquired Pneumonia? - p. 88 19. How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy? - p. 96 20. What Is the Best Approach to the Nonresponding Patient with Community-Acquired Pneumonia? - p. 103 21. What is the Association of Cardiovascular Events with Clinical Failure in Patients with Community-Acquired Pneumonia? - p. 110 22. What is the Role of Antimicrobial Stewardship in Improving Outcomes of Patients with CAP? - p. 113 23. How Effective is Vaccination in Preventing Pneumococcal Disease? - p. 120 24. Index - p. 127
No hay muestra disponible
No hay ficha técnica disponible
